Innate Pharma announces its financial calendar for 2019

INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019
  

Marseille, France, January 10, 2019, 7:00 AM CET

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2019, which is set as follows:

March 20, 2019:         Publication of 2018 financial statements, with management comments.
The 2018 Reference Document and Financial Report (included in the Reference Document) will be released during the second quarter of 2019.

May 15, 2019:            Publication of revenue for 1Q2019, with management comments.

May 22, 2019:            Annual shareholders meeting in Marseille.

September 13, 2019:   Publication of financial statements as of June 30, 2019, with management comments.

November 13, 2019:    Publication of revenue for 3Q2019, with management comments.

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (http://www.innate-pharma.com/en/investors/)

About Innate Pharma:

Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/MedImmune. 

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code Ticker code LEI

FR0010331421 IPH 9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website www.amf-france.org or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors   Innate Pharma  Dr. Markus Metzger / Danielle Spangler / Jérôme Marino Tel.: +33 (0)4 30 30 30 30 investors@innate-pharma.com	International Media   Consilium Strategic Communications Mary-Jane Elliott / Jessica Hodgson Tel.: +44 (0)20 3709 5700 InnatePharma@consilium-comms.com
	French Media   ATCG Press Marie Puvieux Mob: +33 (0)6 10 54 36 72 presse@atcg-partners.com

Attachment

• PR in English